Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC lowered its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 12.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,278 shares of the company’s stock after selling 2,967 shares during the quarter. HighTower Advisors LLC’s holdings in Intellia Therapeutics were worth $415,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after acquiring an additional 1,550 shares in the last quarter. Eastern Bank acquired a new position in shares of Intellia Therapeutics during the third quarter valued at approximately $41,000. Values First Advisors Inc. acquired a new position in shares of Intellia Therapeutics during the third quarter valued at approximately $54,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after purchasing an additional 794 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.20% of the company’s stock.

Intellia Therapeutics Stock Up 0.8 %

NTLA stock opened at $12.18 on Friday. Intellia Therapeutics, Inc. has a twelve month low of $11.79 and a twelve month high of $34.87. The company has a market cap of $1.24 billion, a PE ratio of -2.24 and a beta of 1.76. The business’s 50-day simple moving average is $15.59 and its 200 day simple moving average is $20.26.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.38) EPS. On average, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on NTLA. William Blair restated a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th. The Goldman Sachs Group reduced their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Citigroup cut their price target on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, Stifel Nicolaus decreased their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $54.94.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.